LATS1
LATS1 (large tumour suppressor kinase 1, also known as WARTS) is a serine/threonine kinase of the AGC family that acts as a core component of the Hippo signalling pathway. It restricts proliferation, promotes apoptosis and functions as a tumour suppressor. Browse Assay Genie's current range of LATS1 research reagents below, or read on for the biology behind the target.
LATS1 is a negative regulator of YAP1 in the Hippo signalling pathway, which plays a pivotal role in organ size control and tumour suppression. The core of the pathway is a kinase cascade in which STK3/MST2 and STK4/MST1, in complex with the regulatory protein SAV1, phosphorylate and activate LATS1 and LATS2 in complex with MOB1. The activated kinases in turn phosphorylate and inactivate the YAP1 oncoprotein and WWTR1/TAZ. Phosphorylation of YAP1 by LATS1 inhibits its translocation into the nucleus, where it would otherwise regulate genes controlling cell proliferation, cell death and cell migration.
Beyond Hippo signalling, LATS1 helps maintain ploidy through roles in mitotic progression and the G1 tetraploidy checkpoint. It negatively regulates the G2/M transition by down-regulating CDK1 kinase activity, and it is involved in the control of p53 expression. It affects cytokinesis by regulating actin polymerisation through negative modulation of LIMK1. LATS1 also contributes to mammary gland epithelial cell differentiation, both through the Hippo pathway and through oestrogen receptor signalling by promoting degradation of ESR1, and it may play a role in endocrine function. It can activate the NLRP3 inflammasome by phosphorylating NLRP3 at Ser-265 following NLRP3 palmitoylation, which promotes NLRP3 activation by NEK7.
The LATS1 protein localises to the mitotic apparatus and complexes with CDC2 kinase in early mitosis. It is phosphorylated in a cell-cycle dependent manner, from late prophase through metaphase. Its N-terminal region binds CDC2 and reduces H1 histone kinase activity, consistent with negative regulation of CDC2/cyclin A, and its C-terminal kinase domain binds its own N-terminal region. Knockout mice develop soft-tissue sarcomas and ovarian stromal cell tumours and are highly sensitive to carcinogens. The LATS1 gene was formerly named LATS, large tumour suppressor, homolog 1 (Drosophila), and the mouse ortholog is Lats1.
LATS1 phosphorylates and inactivates YAP1 and WWTR1/TAZ, making it a central kinase for studying organ size control and growth restriction.
LATS1 acts as a tumour suppressor, and knockout mice develop soft-tissue sarcomas and ovarian stromal cell tumours.
LATS1 localises to the mitotic apparatus, binds CDC2 and down-regulates CDK1 activity to restrain the G2/M transition and protect ploidy.
LATS1 phosphorylates NLRP3 to promote activation by NEK7 and promotes ESR1 degradation in mammary epithelial differentiation.
LATS1 is a kinase that negatively regulates YAP1 in the Hippo pathway. Once activated by STK3/MST2 and STK4/MST1 with SAV1, and in complex with MOB1, it phosphorylates YAP1 and WWTR1/TAZ, limiting proliferation and promoting apoptosis. It also controls mitotic progression and ploidy.
LATS1 is also known as WARTS. Earlier gene names were LATS (large tumour suppressor, Drosophila) homolog 1 and LATS, large tumour suppressor, homolog 1 (Drosophila). The UniProt protein name is serine/threonine-protein kinase LATS1, and the HGNC family is the large tumour suppressor kinase family.
Biochemical and genetic data suggest LATS1 is a tumour suppressor. Knockout mice develop soft-tissue sarcomas and ovarian stromal cell tumours and are highly sensitive to carcinogens. The mouse ortholog is Lats1. Check the datasheet of any product for its validated reactivity.
LATS2, other Hippo pathway components, cell cycle regulators and inflammasome targets connected to LATS1 biology.
Gene and protein annotations from HGNC, NCBI Gene and UniProt O95835; product specifications from Assay Genie datasheets.